Age-related macular degeneration 12

Common Name(s)

Age-related macular degeneration 12

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 12" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 12" returned 7 free, full-text research articles on human participants. First 3 results:

Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.
 

Author(s): Xiaoxin Li, Gezhi Xu, Yusheng Wang, Xun Xu, Xiaoling Liu, Shibo Tang, Feng Zhang, Junjun Zhang, Luosheng Tang, Quan Wu, Delun Luo, Xiao Ke,

Journal: Ophthalmology. 2014 Sep;121(9):1740-7.

 

To assess the safety and efficacy of multiple injections of 0.5 and 2.0 mg conbercept using variable dosing regimens in patients with neovascular age-related macular degeneration (AMD).

Last Updated: 25 Aug 2014

Go To URL
Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes.
 

Author(s): Mark C Gillies, Richard Walton, Judy M Simpson, Jennifer J Arnold, Robyn H Guymer, Ian L McAllister, Alex P Hunyor, Rohan W Essex, Nigel Morlet, Daniel Barthelmes,

Journal:

 

We report the 12-month outcomes of 1140 treatment-naïve eyes with exudative age-related macular degeneration (wet AMD) who were treated for 12 months with intravitreal anti-VEGF drugs in routine clinical practice.

Last Updated: 28 Aug 2013

Go To URL
Homocysteine, folate, vitamin B-12, and 10-y incidence of age-related macular degeneration.
 

Author(s): Bamini Gopinath, Victoria M Flood, Elena Rochtchina, Jie Jin Wang, Paul Mitchell

Journal: Am. J. Clin. Nutr.. 2013 Jul;98(1):129-35.

 

Epidemiologic evidence of a relation between serum total homocysteine (tHcy), vitamin B-12, and folate and age-related macular degeneration (AMD) is inconsistent and unresolved.

Last Updated: 21 Jun 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 12" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
 

Status: Not yet recruiting

Condition Summary: Retinal Pigment Epithelial Detachment Secondary to Age-related Macular Degeneration

 

Last Updated: 19 May 2014

Go to URL

Last Updated: 2 Oct 2014

Go to URL
Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START
 

Status: Not yet recruiting

Condition Summary: Neovascular Age-related Macular Degeneration of All Subtypes

 

Last Updated: 18 Sep 2014

Go to URL